DTR — Diagnostear Technologies Share Price
Last trade - 00:00- CA$25.87m
- CA$24.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.99 | ||
| Price to Tang. Book | 10.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -113.23% | ||
| Return on Equity | -1517.25% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DiagnosTear Technologies Inc. is an Israel-based company primarily engaged in the ophthalmic diagnostics industry. The Company focuses on developing and commercializing diagnostic solutions for better management of eye diseases. Their key product is TeaRx, which is a diagnostic platform for Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter analysis of tear fluid. It aims to provide rapid and accurate diagnosis of conditions such as Dry Eye Syndrome (DES) and Red Eye
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- March 10th, 2023
- Public Since
- December 9th, 2024
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 58,788,335
- Address
- Manachem Plant 10, REHOVOT, 7670621
- Web
- Phone
- Auditors
- FAHN KANNE & CO. GRANT THORNTON ISRAEL
Similar to DTR
Aquarius Surgical Technologies
Canadian Securities Exchange
Cannabix Technologies
Canadian Securities Exchange
Gemina Laboratories
Canadian Securities Exchange
Imagin Medical
Canadian Securities Exchange
Izotropic
Canadian Securities Exchange
FAQ
As of Today at 20:14 UTC, shares in Diagnostear Technologies are trading at CA$0.44. This share price information is delayed by 15 minutes.
Shares in Diagnostear Technologies last closed at CA$0.44 and the price had moved by over the past 365 days. In terms of relative price strength the Diagnostear Technologies share price has matched the Toronto Stock Exchange 300 Composite Index by over the past year.
There is no consensus recommendation for this security.
Find out moreDiagnostear Technologies does not currently pay a dividend.
Diagnostear Technologies does not currently pay a dividend.
Diagnostear Technologies does not currently pay a dividend.
To buy shares in Diagnostear Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.44, shares in Diagnostear Technologies had a market capitalisation of CA$25.87m.
Here are the trading details for Diagnostear Technologies:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: DTR
Based on an overall assessment of its quality, value and momentum Diagnostear Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diagnostear Technologies. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -17.24%.
As of the last closing price of CA$0.44, shares in Diagnostear Technologies were trading +0.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Diagnostear Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Diagnostear Technologies' directors